Mechanistic description
This hypothesis proposes engineering therapeutic antibodies with dual functionality: LDLR-binding domains for CNS penetration coupled to anti-inflammatory payloads targeting glial NF-κB signaling. The strategy leverages LDLR’s well-characterized transcytotic properties at the blood-brain barrier to deliver antibodies that specifically suppress microglial and astrocytic inflammatory programs. Upon crossing the BBB via LDLR-mediated transport, these engineered antibodies would target key inflammatory mediators (such as TNF-α, IL-1β, or NF-κB pathway components) within activated glia. This approach addresses the fundamental challenge of neuroinflammation by combining reliable CNS delivery with targeted suppression of the glial inflammatory cascade that drives extracellular adenosine accumulation and downstream ADORA2A pathway activation. The dual-targeting design ensures that anti-inflammatory intervention occurs specifically within the CNS compartment where neuroinflammation originates, rather than relying on systemic anti-inflammatory approaches that may have limited brain penetration. By suppressing glial NF-κB signaling pathways that regulate ectonucleotidase expression and cytokine production, this strategy would reduce the sustained extracellular adenosine tone that contributes to mood circuit dysfunction. The LDLR transport mechanism provides quantifiable, consistent delivery that bypasses the variability inherent in FcRn-dependent transport, while the targeted anti-inflammatory payload addresses the upstream inflammatory processes that drive adenosinergic dysfunction in neuropsychiatric and neurodegenerative conditions.
Evidence for (11)
Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier.
Flaviviruses are neurotropic, but how do they invade the CNS?
Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
GLSP and GLSP-derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis
mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport
Materno-fetal cholesterol transport during pregnancy
Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes
Evidence against (4)
Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier.
PCSK9 in metabolism and diseases.
Functions of lipoprotein receptors in neurons
News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 1 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.